ARM facilitates sustainable access to capital and helps members connect with investors.
Despite the immense economic challenges presented by the COVID-19 pandemic, investors remain bullish on the potential of cell and gene therapies – and the sector as a whole is on track for a record-breaking year. Regenerative medicine and advanced therapy developers have raised $10.7B in financing in the first half of 2020, a 120% increase from the first half of 2019. The public market for cell and gene therapies has been particularly strong. In the first year, five companies went public – including three in the second quarter, in spite of COVID-19 – raising more than $1.4B, with an additional $4B raised in follow-on offerings. In general, the market has been extremely strong, with life sciences stock indices such as the Nasdaq Biotech Index already having made up for any losses incurred during the first weeks of the pandemic.
As the sector continues to grow, ARM brings together members and investors at our events and conferences, providing networking and presentation opportunities, as well as the ability to collaborate via partnering systems.
In addition, ARM’s Quarterly and Sector reports offer investors and members in-depth insight into the current financial and clinical landscape for regenerative medicine. Unique in scope, these reports serve as the preeminent source of information on the global regenerative medicine sector.
ARM’s events bring together industry leaders, investors, policy makers, clinicians and patients to network, partner and learn about the latest clinical and commercial successes and challenges facing the sector.
View the webinar playback featuring Gbola Amusa of Chardan, John Maslowski of Castle Creek Biosciences and Jason Pitts of Sofinnova Investments as they discuss the immense economic challenges brought on by COVID-19 and the impact on investment in the cell and gene therapy space. Topics include the current funding landscape, what investors are looking for when evaluating new and follow-on opportunities, and how companies can best prepare to fundraise during the pandemic.
